Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 243

1.

Chemotherapy use and survival in older adults with metastatic pancreatic cancer in the combination therapy era.

Jain R, Vijayvergia N, Devarajan K, Lewis B, Denlinger CS, Cohen SJ, Dotan E.

J Geriatr Oncol. 2020 Jan 6. pii: S1879-4068(19)30431-X. doi: 10.1016/j.jgo.2019.12.013. [Epub ahead of print]

PMID:
31917116
2.

A phase 1b dose escalation study of Wnt pathway inhibitor vantictumab in combination with nab-paclitaxel and gemcitabine in patients with previously untreated metastatic pancreatic cancer.

Davis SL, Cardin DB, Shahda S, Lenz HJ, Dotan E, O'Neil BH, Kapoun AM, Stagg RJ, Berlin J, Messersmith WA, Cohen SJ.

Invest New Drugs. 2019 Jul 23. doi: 10.1007/s10637-019-00824-1. [Epub ahead of print]

PMID:
31338636
3.

Safety of trifluridine/tipiracil in an open-label expanded-access program in elderly and younger patients with metastatic colorectal cancer.

Mayer RJ, Hochster HS, Cohen SJ, Winkler R, Makris L, Grothey A.

Cancer Chemother Pharmacol. 2018 Dec;82(6):961-969. doi: 10.1007/s00280-018-3686-5. Epub 2018 Oct 22.

PMID:
30350179
4.

A Phase Ib/II Study of the JAK1 Inhibitor, Itacitinib, plus nab-Paclitaxel and Gemcitabine in Advanced Solid Tumors.

Beatty GL, Shahda S, Beck T, Uppal N, Cohen SJ, Donehower R, Gabayan AE, Assad A, Switzky J, Zhen H, Von Hoff DD.

Oncologist. 2019 Jan;24(1):14-e10. doi: 10.1634/theoncologist.2017-0665. Epub 2018 Aug 16.

5.

Phase I/II Trial of Labetuzumab Govitecan (Anti-CEACAM5/SN-38 Antibody-Drug Conjugate) in Patients With Refractory or Relapsing Metastatic Colorectal Cancer.

Dotan E, Cohen SJ, Starodub AN, Lieu CH, Messersmith WA, Simpson PS, Guarino MJ, Marshall JL, Goldberg RM, Hecht JR, Wegener WA, Sharkey RM, Govindan SV, Goldenberg DM, Berlin JD.

J Clin Oncol. 2017 Oct 10;35(29):3338-3346. doi: 10.1200/JCO.2017.73.9011. Epub 2017 Aug 17.

PMID:
28817371
6.

Increased Prevalence of Unusual Sensory Behaviors in Infants at Risk for, and Teens with, Autism Spectrum Disorder.

Van Etten HM, Kaur M, Srinivasan SM, Cohen SJ, Bhat A, Dobkins KR.

J Autism Dev Disord. 2017 Nov;47(11):3431-3445. doi: 10.1007/s10803-017-3227-9.

PMID:
28770526
7.
8.

Baseline hemoglobin and liver function predict tolerability and overall survival of patients receiving radioembolization for chemotherapy-refractory metastatic colorectal cancer.

Kennedy AS, Ball D, Cohen SJ, Cohn M, Coldwell DM, Drooz A, Ehrenwald E, Kanani S, Moeslein FM, Nutting CW, Putnam SG 3rd, Rose SC, Savin M, Schirm S, Sharma NK, Wang E.

J Gastrointest Oncol. 2017 Feb;8(1):70-80. doi: 10.21037/jgo.2017.01.03.

9.

Front-Line Treatment of Metastatic Colorectal Cancer.

Sama AR, Cohen SJ.

J Oncol Pract. 2016 Dec;12(12):1231-1233. No abstract available.

PMID:
27943685
10.
11.

The relationship between sensory latency and amplitude.

Bodofsky EB, Cohen SJ, Kumar RJ, Schindelheim A, Gaughan J.

J Electromyogr Kinesiol. 2016 Dec;31:1-6. doi: 10.1016/j.jelekin.2016.08.008. Epub 2016 Aug 28.

PMID:
27614047
12.

Recombinative Generalization of Tacts Through Matrix Training with Individuals with Autism Spectrum Disorder.

Pauwels AA, Ahearn WH, Cohen SJ.

Anal Verbal Behav. 2015 Sep 28;31(2):200-14. doi: 10.1007/s40616-015-0038-y. eCollection 2015 Oct.

13.

Molecular profiling of neuroendocrine malignancies to identify prognostic and therapeutic markers: a Fox Chase Cancer Center Pilot Study.

Vijayvergia N, Boland PM, Handorf E, Gustafson KS, Gong Y, Cooper HS, Sheriff F, Astsaturov I, Cohen SJ, Engstrom PF.

Br J Cancer. 2016 Aug 23;115(5):564-70. doi: 10.1038/bjc.2016.229. Epub 2016 Aug 2.

14.

Hepatopulmonary Shunting: A Prognostic Indicator of Survival in Patients with Metastatic Colorectal Adenocarcinoma Treated with 90Y Radioembolization.

Narsinh KH, Van Buskirk M, Kennedy AS, Suhail M, Alsaikhan N, Hoh CK, Thurston K, Minocha J, Ball DS, Cohen SJ, Cohn M, Coldwell DM, Drooz A, Ehrenwald E, Kanani S, Nutting CW, Moeslein FM, Savin MA, Schirm S, Putnam SG 3rd, Sharma NK, Wang EA, Rose SC.

Radiology. 2017 Jan;282(1):281-288. doi: 10.1148/radiol.2016152100. Epub 2016 Jul 19.

15.

CALGB 80403 (Alliance)/E1206: A Randomized Phase II Study of Three Chemotherapy Regimens Plus Cetuximab in Metastatic Esophageal and Gastroesophageal Junction Cancers.

Enzinger PC, Burtness BA, Niedzwiecki D, Ye X, Douglas K, Ilson DH, Villaflor VM, Cohen SJ, Mayer RJ, Venook A, Benson AB 3rd, Goldberg RM.

J Clin Oncol. 2016 Aug 10;34(23):2736-42. doi: 10.1200/JCO.2015.65.5092. Epub 2016 Jul 5.

16.

Chemotherapy use and adoption of new agents is affected by age and comorbidities in patients with metastatic colorectal cancer.

Vijayvergia N, Li T, Wong YN, Hall MJ, Cohen SJ, Dotan E.

Cancer. 2016 Oct 15;122(20):3191-3198. doi: 10.1002/cncr.30077. Epub 2016 Jul 5.

17.

Temporary inactivation reveals that the CA1 region of the mouse dorsal hippocampus plays an equivalent role in the retrieval of long-term object memory and spatial memory.

Stackman RW Jr, Cohen SJ, Lora JC, Rios LM.

Neurobiol Learn Mem. 2016 Sep;133:118-128. doi: 10.1016/j.nlm.2016.06.016. Epub 2016 Jun 18.

PMID:
27330015
18.

Examination of the hippocampal contribution to serotonin 5-HT2A receptor-mediated facilitation of object memory in C57BL/6J mice.

Zhang G, Cinalli D, Cohen SJ, Knapp KD, Rios LM, Martínez-Hernández J, Luján R, Stackman RW Jr.

Neuropharmacology. 2016 Oct;109:332-340. doi: 10.1016/j.neuropharm.2016.04.033. Epub 2016 Apr 22.

PMID:
27114257
19.

Dosimetric predictors of hematologic toxicity in patients undergoing concurrent gemcitabine-based chemoradiation for localized pancreatic cancer.

Shaikh T, Wang LS, Egleston B, Burki M, Hoffman JP, Cohen SJ, Meyer JE.

Pract Radiat Oncol. 2016 Jul-Aug;6(4):e107-15. doi: 10.1016/j.prro.2015.11.005. Epub 2015 Nov 14.

PMID:
27032572
20.

Risk of radiation pneumonitis in patients receiving taxane-based trimodality therapy for locally advanced esophageal cancer.

Shaikh T, Churilla TM, Monpara P, Scott WJ, Cohen SJ, Meyer JE.

Pract Radiat Oncol. 2016 Nov - Dec;6(6):388-394. doi: 10.1016/j.prro.2016.02.004. Epub 2016 Feb 27.

21.

Induction Therapy for Locally Advanced, Resectable Esophagogastric Cancer: A Phase I Trial of Vandetanib (ZD6474), Paclitaxel, Carboplatin, 5-Fluorouracil, and Radiotherapy Followed by Resection.

Boland PM, Meyer JE, Berger AC, Cohen SJ, Neuman T, Cooper HS, Olszanski AJ, Davey M, Cheng JD, Lebenthal A, Burtness BA, Scott WJ, Astsaturov IA.

Am J Clin Oncol. 2017 Aug;40(4):393-398. doi: 10.1097/COC.0000000000000171.

22.

Prognostic Significance of MUC-1 in Circulating Tumor Cells in Patients With Metastatic Pancreatic Adenocarcinoma.

Dotan E, Alpaugh RK, Ruth K, Negin BP, Denlinger CS, Hall MJ, Astsaturov I, McAleer C, Fittipaldi P, Thrash-Bingham C, Meropol NJ, Cohen SJ.

Pancreas. 2016 Sep;45(8):1131-5. doi: 10.1097/MPA.0000000000000619.

23.

A phase II/III randomized study to compare the efficacy and safety of rigosertib plus gemcitabine versus gemcitabine alone in patients with previously untreated metastatic pancreatic cancer.

O'Neil BH, Scott AJ, Ma WW, Cohen SJ, Aisner DL, Menter AR, Tejani MA, Cho JK, Granfortuna J, Coveler AL, Olowokure OO, Baranda JC, Cusnir M, Phillip P, Boles J, Nazemzadeh R, Rarick M, Cohen DJ, Radford J, Fehrenbacher L, Bajaj R, Bathini V, Fanta P, Berlin J, McRee AJ, Maguire R, Wilhelm F, Maniar M, Jimeno A, Gomes CL, Messersmith WA.

Ann Oncol. 2016 Jun;27(6):1180. doi: 10.1093/annonc/mdw095. Epub 2016 Mar 3. No abstract available.

24.

A phase 1b study of erlotinib in combination with gemcitabine and nab-paclitaxel in patients with previously untreated advanced pancreatic cancer: an Academic Oncology GI Cancer Consortium study.

Cohen SJ, O'Neil BH, Berlin J, Ames P, McKinley M, Horan J, Catalano PM, Davies A, Weekes CD, Leichman L.

Cancer Chemother Pharmacol. 2016 Apr;77(4):693-701. doi: 10.1007/s00280-016-2981-2. Epub 2016 Feb 17.

PMID:
26886016
25.

Phase II Study of Olaparib (AZD-2281) After Standard Systemic Therapies for Disseminated Colorectal Cancer.

Leichman L, Groshen S, O'Neil BH, Messersmith W, Berlin J, Chan E, Leichman CG, Cohen SJ, Cohen D, Lenz HJ, Gold P, Boman B, Fielding A, Locker G, Cason RC, Hamilton SR, Hochster HS.

Oncologist. 2016 Feb;21(2):172-7. doi: 10.1634/theoncologist.2015-0319. Epub 2016 Jan 19.

26.

Young Age Increases Risk of Lymph Node Positivity in Early-Stage Rectal Cancer.

Meyer JE, Cohen SJ, Ruth KJ, Sigurdson ER, Hall MJ.

J Natl Cancer Inst. 2016 Jan;108(1). doi: 10.1093/jnci/djv284.

27.

A Phase 2 Randomized, Double-Blind, Multicenter Trial of Imexon Plus Gemcitabine Versus Gemcitabine Plus Placebo in Patients With Metastatic Chemotherapy-naïve Pancreatic Adenocarcinoma.

Cohen SJ, Zalupski MM, Conkling P, Nugent F, Ma WW, Modiano M, Pascual R, Lee FC, Wong L, Hersh E.

Am J Clin Oncol. 2018 Mar;41(3):230-235. doi: 10.1097/COC.0000000000000260.

PMID:
26709865
28.

Hepatic imaging response to radioembolization with yttrium-90-labeled resin microspheres for tumor progression during systemic chemotherapy in patients with colorectal liver metastases.

Kennedy AS, Ball DS, Cohen SJ, Cohn M, Coldwell DM, Drooz A, Ehrenwald E, Kanani S, Nutting CW, Moeslein FM, Putnam SG 3rd, Rose SC, Savin MA, Schirm S, Sharma NK, Wang EA.

J Gastrointest Oncol. 2015 Dec;6(6):594-604. doi: 10.3978/j.issn.2078-6891.2015.082.

29.

Patterns and predictors of failure following tri-modality therapy for locally advanced esophageal cancer.

Shaikh T, Zaki MA, Dominello MM, Handorf E, Konski AA, Cohen SJ, Shields A, Philip P, Meyer JE.

Acta Oncol. 2016;55(3):303-8. doi: 10.3109/0284186X.2015.1110252. Epub 2015 Nov 19.

30.

Safety and Efficacy of Radioembolization in Elderly (≥ 70 Years) and Younger Patients With Unresectable Liver-Dominant Colorectal Cancer.

Kennedy AS, Ball DS, Cohen SJ, Cohn M, Coldwell D, Drooz A, Ehrenwald E, Kanani S, Rose SC, Nutting CW, Moeslein FM, Savin MA, Schirm S, Putnam SG 3rd, Sharma NK, Wang EA; Metastatic Colorectal Cancer Liver Metastases Outcomes After Radioembolization (MORE) Study Investigators.

Clin Colorectal Cancer. 2016 Jun;15(2):141-151.e6. doi: 10.1016/j.clcc.2015.09.001. Epub 2015 Nov 2.

31.

A phase II/III randomized study to compare the efficacy and safety of rigosertib plus gemcitabine versus gemcitabine alone in patients with previously untreated metastatic pancreatic cancer.

O'Neil BH, Scott AJ, Ma WW, Cohen SJ, Leichman L, Aisner DL, Menter AR, Tejani MA, Cho JK, Granfortuna J, Coveler L, Olowokure OO, Baranda JC, Cusnir M, Phillip P, Boles J, Nazemzadeh R, Rarick M, Cohen DJ, Radford J, Fehrenbacher L, Bajaj R, Bathini V, Fanta P, Berlin J, McRee AJ, Maguire R, Wilhelm F, Maniar M, Jimeno A, Gomes CL, Messersmith WA.

Ann Oncol. 2015 Dec;26(12):2505. doi: 10.1093/annonc/mdv477. Epub 2015 Oct 21. No abstract available.

32.

Association of treatment factors with surgical outcomes in tri-modality therapy for esophageal cancer.

Shaikh T, Thomay A, Ruth K, Cohen SJ, Meyer JE.

J Surg Oncol. 2015 Nov;112(6):629-33. doi: 10.1002/jso.24060. Epub 2015 Oct 2.

PMID:
26430952
33.

Predictors of Hematologic Toxicity and Chemotherapy Dose Intensity in Patients Undergoing Chemoradiation for Pancreatic Cancer.

Shaikh T, Wang LS, Egleston B, Burki M, Hoffman JP, Cohen SJ, Meyer JE.

Am J Clin Oncol. 2018 Jan;41(1):59-64. doi: 10.1097/COC.0000000000000227.

34.

Patterns of care and outcomes of older versus younger patients with metastatic pancreatic cancer: A Fox Chase Cancer Center experience.

Vijayvergia N, Dotan E, Devarajan K, Hatahet K, Rahman F, Ricco J, Lewis B, Gupta S, Cohen SJ.

J Geriatr Oncol. 2015 Nov;6(6):454-61. doi: 10.1016/j.jgo.2015.08.001. Epub 2015 Aug 18.

35.

(90)Y-clivatuzumab tetraxetan with or without low-dose gemcitabine: A phase Ib study in patients with metastatic pancreatic cancer after two or more prior therapies.

Picozzi VJ, Ramanathan RK, Lowery MA, Ocean AJ, Mitchel EP, O'Neil BH, Guarino MJ, Conkling PR, Cohen SJ, Bahary N, Frank RC, Dragovich T, Bridges BB, Braiteh FS, Starodub AN, Lee FC, Gribbin TE, Richards DA, Lee M, Korn RL, Pandit-Taskar N, Goldsmith SJ, Intenzo CM, Sheikh A, Manzone TC, Horne H, Sharkey RM, Wegener WA, O'Reilly EM, Goldenberg DM, Von Hoff DD.

Eur J Cancer. 2015 Sep;51(14):1857-64. doi: 10.1016/j.ejca.2015.06.119. Epub 2015 Jul 14.

36.

A phase II/III randomized study to compare the efficacy and safety of rigosertib plus gemcitabine versus gemcitabine alone in patients with previously untreated metastatic pancreatic cancer.

O'Neil BH, Scott AJ, Ma WW, Cohen SJ, Leichman L, Aisner DL, Menter AR, Tejani MA, Cho JK, Granfortuna J, Coveler AL, Olowokure OO, Baranda JC, Cusnir M, Phillip P, Boles J, Nazemzadeh R, Rarick M, Cohen DJ, Radford J, Fehrenbacher L, Bajaj R, Bathini V, Fanta P, Berlin J, McRee AJ, Maguire R, Wilhelm F, Maniar M, Jimeno A, Gomes CL, Messersmith WA.

Ann Oncol. 2015 Sep;26(9):1923-9. doi: 10.1093/annonc/mdv264. Epub 2015 Jun 19. Erratum in: Ann Oncol. 2015 Dec;26(12):2505. Leichman, L [added]. Ann Oncol. 2016 Jun;27(6):1180.

37.

Dose escalation with a vessel boost in pancreatic adenocarcinoma treated with neoadjuvant chemoradiation.

Wang LS, Shaikh T, Handorf EA, Hoffman JP, Cohen SJ, Meyer JE.

Pract Radiat Oncol. 2015 Sep-Oct;5(5):e457-e463. doi: 10.1016/j.prro.2015.04.004. Epub 2015 Jun 12.

38.
39.

Multicenter evaluation of the safety and efficacy of radioembolization in patients with unresectable colorectal liver metastases selected as candidates for (90)Y resin microspheres.

Kennedy AS, Ball D, Cohen SJ, Cohn M, Coldwell DM, Drooz A, Ehrenwald E, Kanani S, Rose SC, Nutting CW, Moeslein FM, Savin MA, Schirm S, Putnam SG 3rd, Sharma NK, Wang EA.

J Gastrointest Oncol. 2015 Apr;6(2):134-42. doi: 10.3978/j.issn.2078-6891.2014.109.

40.

Multi-institutional phase I study of low-dose ultra-fractionated radiotherapy as a chemosensitizer for gemcitabine and erlotinib in patients with locally advanced or limited metastatic pancreatic cancer.

Konski A, Meyer JE, Joiner M, Hall MJ, Philip P, Shields A, McSpadden E, Choi M, Adaire B, Duncan G, Meropol NJ, Cescon TP, Cohen SJ.

Radiother Oncol. 2014 Oct;113(1):35-40. doi: 10.1016/j.radonc.2014.08.014. Epub 2014 Oct 20.

PMID:
25441058
41.

Increased time from neoadjuvant chemoradiation to surgery is associated with higher pathologic complete response rates in esophageal cancer.

Shaikh T, Ruth K, Scott WJ, Burtness BA, Cohen SJ, Konski AA, Cooper HS, Astsaturov I, Meyer JE.

Ann Thorac Surg. 2015 Jan;99(1):270-6. doi: 10.1016/j.athoracsur.2014.08.033. Epub 2014 Nov 18.

42.

Contraction induced h reflexes in the diagnosis of cervical radiculopathy.

Bodofsky EB, Campellone JV, Cohen SJ, Caten HN, Schindelheim AM.

J Clin Neurophysiol. 2015 Jun;32(3):244-6. doi: 10.1097/WNP.0000000000000152.

PMID:
25420157
43.

Assessing rodent hippocampal involvement in the novel object recognition task. A review.

Cohen SJ, Stackman RW Jr.

Behav Brain Res. 2015 May 15;285:105-17. doi: 10.1016/j.bbr.2014.08.002. Epub 2014 Aug 26. Review.

PMID:
25169255
44.

Systemic therapy for advanced appendiceal adenocarcinoma: an analysis from the NCCN Oncology Outcomes Database for colorectal cancer.

Tejani MA, ter Veer A, Milne D, Ottesen R, Bekaii-Saab T, Benson AB 3rd, Schrag D, Shibata S, Skibber J, Weiser M, Wilkinson N, Cohen SJ.

J Natl Compr Canc Netw. 2014 Aug;12(8):1123-30.

PMID:
25099444
45.

Pancreatic adenocarcinoma, version 2.2014: featured updates to the NCCN guidelines.

Tempero MA, Malafa MP, Behrman SW, Benson AB 3rd, Casper ES, Chiorean EG, Chung V, Cohen SJ, Czito B, Engebretson A, Feng M, Hawkins WG, Herman J, Hoffman JP, Ko A, Komanduri S, Koong A, Lowy AM, Ma WW, Merchant NB, Mulvihill SJ, Muscarella P 2nd, Nakakura EK, Obando J, Pitman MB, Reddy S, Sasson AR, Thayer SP, Weekes CD, Wolff RA, Wolpin BM, Burns JL, Freedman-Cass DA.

J Natl Compr Canc Netw. 2014 Aug;12(8):1083-93.

PMID:
25099441
46.

Patterns of use and tolerance of anti-epidermal growth factor receptor antibodies in older adults with metastatic colorectal cancer.

Dotan E, Devarajan K, D'Silva AJ, Beck A, Kloth DD, Cohen SJ, Denlinger C.

Clin Colorectal Cancer. 2014 Sep;13(3):192-8. doi: 10.1016/j.clcc.2014.05.003. Epub 2014 Jun 26.

47.

Phase I study of capecitabine combined with radioembolization using yttrium-90 resin microspheres (SIR-Spheres) in patients with advanced cancer.

Cohen SJ, Konski AA, Putnam S, Ball DS, Meyer JE, Yu JQ, Astsaturov I, Marlow C, Dickens A, Cade DN, Meropol NJ.

Br J Cancer. 2014 Jul 15;111(2):265-71. doi: 10.1038/bjc.2014.344. Epub 2014 Jul 1.

48.

Successful imatinib therapy for neuroendocrine carcinoma with activating Kit mutation: a case study.

Perkins J, Boland P, Cohen SJ, Olszanski AJ, Zhou Y, Engstrom P, Astsaturov I.

J Natl Compr Canc Netw. 2014 Jun;12(6):847-52.

49.

The neurosteroid allopregnanolone impairs object memory and contextual fear memory in male C57BL/6J mice.

Rabinowitz A, Cohen SJ, Finn DA, Stackman RW Jr.

Horm Behav. 2014 Jul;66(2):238-46. doi: 10.1016/j.yhbeh.2014.05.005. Epub 2014 May 26.

PMID:
24874172
50.

Women at increased risk for cardiac toxicity following chemoradiation therapy for esophageal carcinoma.

Tait LM, Meyer JE, McSpadden E, Cheng JD, Baciewicz FA, Meropol NJ, Cohen SJ, Wozniak AJ, Choi M, Konski AA.

Pract Radiat Oncol. 2013 Oct-Dec;3(4):e149-55. doi: 10.1016/j.prro.2013.02.001. Epub 2013 Mar 13.

PMID:
24674412

Supplemental Content

Loading ...
Support Center